Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Author: search.filters.author.Aleksandra TatabitovskaLanguage: search.filters.language.English

Search Results

Now showing 1 - 3 of 3
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    CELLULAR AND HUMORAL IMMUNITY IN PATIENTS WITH COVID-19 CORRELATED WITH SEVERITY OF CLINICAL PRESENTATION AND SARS COV-2 VACCINATION STATUS
    (Македонско лекарско друштво = Macedonian medical association, 2024)
    Aleksandra Tatabitovska
    ;
    ;
    ;
    Dejan Todevski
    ;
    Introduction. The COVID-19 pandemic has changed life across the planet, claiming approximately 7 mi- llion lives and more than 776 million cases reported globally, leaving many people with lasting sequelae. Of particular importance is understanding the immune system's defense responses against SARS-CoV-2 infection, with an emphasis on T-lymphocyte cells that modulate both cellular and humoral part. Aims. To determine epidemiological and clinical featu- res, especially comorbidities in patients who have had severe and mild COVID-19, to determine differences in cellular and humoral immune response and to co- rrelate with vaccination status for SARS CoV-2. Methods. A 6-month-prospective cohort study was conducted at the University Clinic for Pulmonology and Allergology and the Institute of Immunobiology and Human Genetics at the Faculty of Medicine - Skopje. The study included 88 patients with pre-exis- ting COVID-19 divided into two groups: patients with mild clinical manifestations and patients with severe clinical manifestations requiring hospitalization. The parameters of patients' medical history, number and type of comorbidities, parameters of cellular and hu- moral immune response, data on vaccination against SARS-CoV-2 were analyzed. Conclusion. The severity of the clinical presentation correlated directly with the number of comorbidities, and inversely with the vaccination status. Comorbidi- ties were present in 87.7% of patients with a severe clinical course. No correlation was found with the smoking status. The study showed that 97.72% of all patients had positive neutralizing antibodies for SARS- CoV-2. Positive cellular immunity had 54.55% of pa- tients, significantly higher in the group with severe COVID-19 and vaccinated patients. There was a posi- tive correlation between cellular and humoral immu- nity, but in 2 cases (4.16%) where the humoral respon- se was absent, a positive cellular response was verified.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    ADENOID CYSTİC CARCINOMA TREATED WITH ELECTROCAUTERY– 5-YEAR SURVIVAL
    (Македонско лекарско друштво = Macedonian Medical Association, 2020)
    Arben Rexhepi
    ;
    ;
    Dejan Todevski
    ;
    Aleksandra Tatabitovska
    ;
    Adenoid cystic carcinoma (ACC) is an uncommon neoplasm which arises from the major and minor salivary glands of the head and neck. Rarely, it can develop from secretory glands originating in the trachea, breast, lacrimal glands or other exocrine glands. We present a case of a fifty-years-old female patient with a polypoid adenoid ACC, growing from the middle of the left main bronchus causing obstruction of the bronchial lumen. Complete resection of the polypoid mass was accomplished using an electrocautery snare through the flexible bronchoscope, cauterizing the stalk in one attempt. The tumor was extracted in the manner of foreign body extraction, attaining complete recanalization and providing patency of the visible bronchial tree with no immediate or late complications. The followup bronchoscopy after 6 months found no signs of persistent or recurrent disease. The patient was followed at 6 and 12 months and every year for 5 years and no signs for local recidive or metastasis was found. We recommend considering endoscopic electrocautery for selected endobronchial or endotracheal cases of ACC, where surgical or oncologic treatment is not possible, in curative or palliative purposes.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Consensus statement: RECOMMENDATIONS FOR THE DIAGNOSTIC ALGORITHM IN LUNG CANCER CONSENSUS STATEMENT OF THE MACEDONIAN RESPIRATORY SOCIETY AND THE MACEDONIAN ASSOCIATION OF PATHOLOGY
    (Македонско лекарско друштво = Macedonian Medical Association, 2019)
    ;
    Dejan Todevski
    ;
    Arben Rexhepi
    ;
    Aleksandra Tatabitovska
    ;
    Lung cancer is the “number one cancer killer” in the world. Its prevalence is associated with smoking as the primary cause, although air pollution in general and genetic factors are also important. The mortality especially from advanced stage lung cancer is still high, although there has been a significant improvement in the past 10 years, mostly due to the introduction of novel compounds such as targeted and immunological treatment. The advances in the treatment of NSCLC have imposed updating of the guidelines for the diagnostic procedure and screening of LC, for the indications for molecular testing as well as for targeted selection of patients who shall benefit the most from the novel treatment modalities. These recommendations shall fulfil their purpose only if implemented in the educational curriculum and if incorporated in the healthcare system strategies.